Panome Bio

Panome Bio is a biotechnology company based in St. Louis, Missouri, founded in 2022. The company specializes in metabolomics, lipidomics, and proteomics, focusing on advancing functional phenotyping. Panome Bio aims to address significant biological questions through biomarker discovery and metabolism profiling, supporting research and development in the life sciences sector. The company offers a range of services, including next-generation metabolomics using untargeted mass spectrometry technology, which allows for the identification of biologically relevant metabolites. Additionally, Panome Bio provides high-throughput proteomics assays in partnership with Somalogic, enabling comprehensive profiling of proteins. Their integrated multi-omics technology combines metabolomics and proteomics data to deliver deeper insights into biological systems and metabolic pathways. Panome Bio has secured approximately $6 million in funding through a Series A investment round, with support from investors such as Telegraph Hill Partners, BioGenerator Ventures, and Cultivation Capital. The company's advanced liquid chromatography-mass spectrometry assays and proprietary bioinformatic tools enhance its ability to provide actionable insights into metabolic pathways.